Page last updated: 2024-12-07

benzoylphenylalanine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Benzoylphenylalanine (Bpa) is a synthetic amino acid derivative that has been studied for its potential therapeutic applications. It is typically synthesized through the reaction of benzoyl chloride with L-phenylalanine in the presence of a base. Bpa is known to exhibit several pharmacological effects, including anti-inflammatory, analgesic, and anti-cancer activities. It is believed to exert its effects by modulating various signaling pathways, such as the nuclear factor kappa-B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways. The anti-inflammatory properties of Bpa have led to investigations into its potential use in treating inflammatory diseases like rheumatoid arthritis and inflammatory bowel disease. Moreover, its anti-cancer activity has prompted research exploring its efficacy in treating various types of cancer. Bpa is also being studied for its potential as a neuroprotective agent, with research suggesting it may play a role in protecting against neuronal damage caused by oxidative stress. Due to its diverse pharmacological effects and potential therapeutic applications, Bpa continues to be an active area of scientific research.'

N-benzoyl-DL-phenylalanine : A racemate comprising equimolar amounts of N-benzoyl-D- and N-benzoyl-L-phenylalanine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

2-(benzoylamino)-3-phenylpropanoic acid : A member of the class of benzamides that is 3-phenylpropanoic acid in which one of the hydrogens at position 2 has been replaced by a benzoylamino group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

N-benzoyl-L-phenylalanine : An N-acyl-L-phenylalanine that is L-phenylalanine in which one of the hydrogens of the amino group has been replaced by a benzoyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID273362
CHEMBL ID67572
CHEBI ID90419
SCHEMBL ID111235
MeSH IDM0152185
PubMed CID97370
CHEMBL ID22685
CHEBI ID90412
SCHEMBL ID111236
MeSH IDM0152185

Synonyms (95)

Synonym
nsc-96354
nsc96354
2901-76-0
smr000062385
MLS000048365
OPREA1_754356
nsc-118532
nsc118532
93059-41-7
nsc167264
nsc-167264
n-benzoyl-dl-phenylalanine
NCIOPEN2_007081
n-(phenylcarbonyl)phenylalanine
STK078967
B0302
benzoyl-dl-phenylalanine
AKOS000273933
CHEMBL67572
chebi:90419 ,
2-benzamido-3-phenylpropanoic acid
HMS1659K12
BBL014468
n-benzoylphenylalanine
3-phenyl-2-(phenylformamido)propanoic acid
A819721
HMS2288N06
FT-0634543
phenylalanine,n-benzoyl-
F3095-4679
SCHEMBL111235
AKOS016040290
2J-369S
n-benzoyl-d,l-phenylalanine
n-benzoylphenylalanine #
benzoyl-d-phe-oh
2-(benzoylamino)-3-phenylpropionic acid
2-(benzoylamino)-3-phenylpropanoic acid
phenylalanine, n-benzoyl-
mfcd00037252
VU0509001-1
Z85881058
2-benzamido-3-phenylpropanoicacid
bz-dl-phe-oh
J-017354
Q27162531
1,1,3-trimethyl-3-phenylindan-4,5-dicarboxylicacid
F10835
DTXSID301311364
CS-0186555
EN300-00202
HY-W128407
SY034294
n-benzoyl-l-phenylalanine
l-phenylalanine, n-benzoyl-
SDCCGMLS-0091886.P001
2566-22-5
UPCMLD11ADMT003156:001
NCGC00142256-01
benzoylphenylalanine
CHEMBL22685
chebi:90412 ,
(2s)-2-benzamido-3-phenylpropanoic acid
AKOS001041864
nsc 118532
unii-9s304jl9m7
9s304jl9m7 ,
bz-phe-oh
AB01209950-01
AB01209950-04
SCHEMBL111236
benzoyl-l-phenylalanine
n-benzoyl phenylalanine
n-benzoyl phenyalanine
nalpha-benzoyl-l-phenylalanine
nalpha -benzoylphenylalanine
mfcd00063153
n-alpha-benzoyl-l-phenylalanine (bz-l-phe-oh)
n-benzoylphenylalanine, l-
(2s)-2-(benzoylamino)-3-phenylpropanoic acid
(s)-2-benzamido-3-phenylpropanoic acid
n-benzoyl-(s)-phenylalanine
(s)-2-benzamido-3-phenylpropionic acid
bz-l-phe-oh
n(alpha)-benzoyl-l-phenylalanine
l-phenylalanine,n-benzoyl-
Z56891330
Q27162527
AS-17698
bzo-phe-oh
A877515
NCGC00142256-03
DTXSID701313598
(s)-2-benzoylamino-3-phenyl-propionic acid
CS-0065813
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
N-acyl-amino acidA carboxamide resulting from the formal condensation of a carboxylic acid with the amino group of an amino acid.
benzamides
N-acyl-L-phenylalanineAny N-acyl-L-amino acid obtained by the formal N-acylation of L-phenylalanine.
2-(benzoylamino)-3-phenylpropanoic acidA member of the class of benzamides that is 3-phenylpropanoic acid in which one of the hydrogens at position 2 has been replaced by a benzoylamino group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID130089Hypoglycemic activity at the lowest dose that causing 20% blood glucose decrease (fasting mice, po)1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
N-acylphenylalanines and related compounds. A new class of oral hypoglycemic agents.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID197595Lysozyme-conjugated prodrugs: in vitro stability at pH 51992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID130089Hypoglycemic activity at the lowest dose that causing 20% blood glucose decrease (fasting mice, po)1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
N-acylphenylalanines and related compounds. A new class of oral hypoglycemic agents.
AID1148042Antitumor activity against mouse EAC allografted in CF1 mouse assessed as inhibition of tumor growth at 33 mg/kg/day measured on day 71977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antineoplastic agents. 1. N-Protected vinyl, 1,2-dihaloethyl, and cyanomethyl esters of phenylalanine.
AID1148040Antitumor activity against mouse EAC allografted in CF1 mouse assessed as host survival at 33 mg/kg/day measured on day 71977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antineoplastic agents. 1. N-Protected vinyl, 1,2-dihaloethyl, and cyanomethyl esters of phenylalanine.
AID197597Lysozyme-conjugated prodrugs: in vitro stability at pH 7.41992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID1148041Antitumor activity against mouse EAC allografted in CF1 mouse assessed as tumor volume at 33 mg/kg/day measured on day 71977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antineoplastic agents. 1. N-Protected vinyl, 1,2-dihaloethyl, and cyanomethyl esters of phenylalanine.
AID197601Lysozyme-conjugated prodrugs: in vitro stability at pH 7.41992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID197599Lysozyme-conjugated prodrugs: in vitro stability at pH 51992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (76)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (7.89)18.7374
1990's21 (27.63)18.2507
2000's32 (42.11)29.6817
2010's15 (19.74)24.3611
2020's2 (2.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.15 (24.57)
Research Supply Index4.29 (2.92)
Research Growth Index4.85 (4.65)
Search Engine Demand Index30.00 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews1 (1.39%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
Other71 (98.61%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]